<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00982566</url>
  </required_header>
  <id_info>
    <org_study_id>M11-069</org_study_id>
    <nct_id>NCT00982566</nct_id>
  </id_info>
  <brief_title>Assess the Oral Bioavailability of a New ABT-263 Formulation in Subjects With Cancer</brief_title>
  <official_title>A Phase 1 Study Evaluating the Relative Oral Bioavailability of New Formulations of ABT-263 in Subjects With Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>AbbVie</source>
  <brief_summary>
    <textblock>
      This is a randomized, single dose, open-label, multicenter crossover study to determine the&#xD;
      oral bioavailability of a new ABT-263 formulation relative to that of the current ABT-263&#xD;
      formulation being administered in ongoing Phase 1/2a studies. Approximately 48 evaluable&#xD;
      subjects with lymphoid malignancies, including chronic lymphocytic leukemia, and solid tumors&#xD;
      will be enrolled in this study.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects who complete Part 1 of the study will be provided an opportunity to receive&#xD;
      Formulation A under a continuous once daily dosing schedule during Part 2 of the study.&#xD;
      Subjects enrolled in the second part of the study may continue to receive Formulation A under&#xD;
      the continuous once daily dosing schedule for up to one year following the date of the last&#xD;
      subject enrolled on study provided they continue to tolerate the drug, have no evidence of&#xD;
      disease progression, and do not meet any of the protocol specific criteria for subject&#xD;
      discontinuation.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2009</start_date>
  <completion_date type="Actual">December 2010</completion_date>
  <primary_completion_date type="Actual">October 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assessment of Oral Bioavailability</measure>
    <time_frame>Two Period and Three Period crossover design</time_frame>
    <description>Assess the oral bioavailability of Formulation B1, Formulation B2, Formulation C, and Formulation D relative to that of Formulation A being assessed in ongoing Phase 1/2a ABT-263 studies</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse Events Tabulation</measure>
    <time_frame>Two Period and Three Period crossover design</time_frame>
    <description>Safety measures include number and percentage of subjects having treatment-emergent adverse events tabulated by MedDRA system organ class and preferred term, laboratory test results, lymphocyte enumeration results, vital signs, etc.</description>
  </secondary_outcome>
  <number_of_arms>16</number_of_arms>
  <enrollment type="Actual">37</enrollment>
  <condition>Lymphoid Malignancy</condition>
  <condition>Solid Tumors</condition>
  <arm_group>
    <arm_group_label>Sequence I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence II</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence III</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence IV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence V</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence VI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence VII</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence VIII</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence IX</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence X</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence XI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence XII</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence XIII</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence XIV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence XVI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence XV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ABT-263</intervention_name>
    <description>Part 1: Single (oral) dose of 250 mg of Formulation B1 vs. single (oral) dose of 250 mg of Formulation A</description>
    <arm_group_label>Sequence I</arm_group_label>
    <arm_group_label>Sequence II</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ABT-263</intervention_name>
    <description>Part 1 continued. Single (oral) dose of 250 mg of Formulation B2 vs. single (oral) dose of 250 mg of Formulation A</description>
    <arm_group_label>Sequence III</arm_group_label>
    <arm_group_label>Sequence IV</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ABT-263</intervention_name>
    <description>Part 1: Single (oral) dose of 200 mg of Formulation C vs. single (oral) dose of 200 mg of Formulation A</description>
    <arm_group_label>Sequence IX</arm_group_label>
    <arm_group_label>Sequence V</arm_group_label>
    <arm_group_label>Sequence VI</arm_group_label>
    <arm_group_label>Sequence VII</arm_group_label>
    <arm_group_label>Sequence VIII</arm_group_label>
    <arm_group_label>Sequence X</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ABT-263</intervention_name>
    <description>Part 1: Single (oral) dose of 200 mg of Formulation C vs. single (oral) dose of 200 mg of Formulation A</description>
    <arm_group_label>Sequence XI</arm_group_label>
    <arm_group_label>Sequence XII</arm_group_label>
    <arm_group_label>Sequence XIII</arm_group_label>
    <arm_group_label>Sequence XIV</arm_group_label>
    <arm_group_label>Sequence XV</arm_group_label>
    <arm_group_label>Sequence XVI</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subject must be &gt;= 18 years of age.&#xD;
&#xD;
          2. Subject has a lymphoid malignancy (histologic or cytologic confirmation), or solid&#xD;
             tumor (radiographic, histologic, or cytologic confirmation) that is either:&#xD;
&#xD;
               -  relapsed or refractory to standard therapy, or&#xD;
&#xD;
               -  no known effective therapy exists.&#xD;
&#xD;
          3. In the investigator's opinion, the subject's life expectancy is at least 90 days.&#xD;
&#xD;
          4. Subjects with known brain metastases must have clinically controlled neurologic&#xD;
             symptoms, defined as surgical excision and/or radiation therapy followed by 21 days of&#xD;
             stable neurologic function and no evidence of CNS disease progression as determined by&#xD;
             CT or MRI within 21 days prior to the first dose of study drug.&#xD;
&#xD;
          5. If clinically indicated, subjects must have documented brain imaging (MRI or CT)&#xD;
             negative for subdural or epidural hematoma within 28 days prior to the first dose of&#xD;
             study drug.&#xD;
&#xD;
          6. Subject has an Eastern Cooperative Oncology Group (ECOG) performance score of &lt;= 2.&#xD;
&#xD;
          7. Subject must have adequate bone marrow, renal and hepatic function per local&#xD;
             laboratory reference range as follows:&#xD;
&#xD;
               -  Bone marrow: Absolute Neutrophil count (ANC) &gt;= 1,000/ÂµL; Platelets &gt;=&#xD;
                  100,000/mm3 (independent of platelet transfusions within 3 months prior to&#xD;
                  starting study drug); Hemoglobin &gt;= 9.0 g/dL;&#xD;
&#xD;
               -  Renal function: serum creatinine &lt;= 2.0 mg/dL or calculated creatinine clearance&#xD;
                  &gt;= 50 mL/min;&#xD;
&#xD;
               -  Hepatic function and enzymes: AST and ALT &lt;= 2.5 x the upper normal limit (ULN)&#xD;
                  of institution's normal range; Bilirubin &lt;= 1.5 x ULN. Subjects with Gilbert's&#xD;
                  Syndrome may have a Bilirubin &gt; 1.5 x ULN; Subjects with liver metastasis may&#xD;
                  have an AST and ALT of &lt;= 5.0 x ULN;&#xD;
&#xD;
               -  Coagulation: aPTT, PT not to exceed 1.2 x ULN.&#xD;
&#xD;
          8. Female subjects must be surgically sterile, postmenopausal (for at least one year), or&#xD;
             have negative results for a pregnancy test performed as follows:&#xD;
&#xD;
               -  At Screening on a serum sample obtained within 14 days prior to initial study&#xD;
                  drug administration, and&#xD;
&#xD;
               -  Prior to start of dosing on a urine sample if it has been &gt; 7 days since&#xD;
                  obtaining the serum pregnancy test results.&#xD;
&#xD;
          9. Female subjects not surgically sterile or postmenopausal (for at least one year) and&#xD;
             non-vasectomized male subjects must practice at least one of the following methods of&#xD;
             birth control:&#xD;
&#xD;
               -  total abstinence from sexual intercourse (minimum one complete menstrual cycle&#xD;
                  prior to starting study drug);&#xD;
&#xD;
               -  a vasectomized partner;&#xD;
&#xD;
               -  hormonal contraceptives (oral, parenteral or transdermal) for at least three&#xD;
                  months prior to study drug administration;&#xD;
&#xD;
               -  double-barrier method (including condoms, contraceptive sponge, diaphragm or&#xD;
                  vaginal ring with spermicidal jellies or cream).&#xD;
&#xD;
         10. Subject must voluntarily sign and date an informed consent, approved by an Independent&#xD;
             Ethics Committee (IEC)/Institutional Review Board (IRB), prior to the initiation of&#xD;
             any screening or study-specific procedures.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subject has undergone an allogeneic stem cell transplant.&#xD;
&#xD;
          2. Subject has an underlying condition predisposing them to bleeding or currently&#xD;
             exhibits signs of clinically significant bleeding.&#xD;
&#xD;
          3. Subject has a recent history of non-chemotherapy induced thrombocytopenic associated&#xD;
             bleeding within one year prior to the first dose of study drug.&#xD;
&#xD;
          4. Subject has active peptic ulcer disease or other hemorrhagic esophagitis/gastritis.&#xD;
&#xD;
          5. Subject has a significant history of cardiovascular disease (e.g., MI, thrombotic or&#xD;
             thromboembolic event in the last 6 months), renal, neurologic, psychiatric,&#xD;
             endocrinologic, metabolic, immunologic, or hepatic disease that in the opinion of the&#xD;
             investigator would adversely affect his/her participating in this study. Questions&#xD;
             regarding inclusion of individual subjects should be directed to the Abbott Medical&#xD;
             Monitor or designee.&#xD;
&#xD;
          6. Female subject is pregnant or breast-feeding.&#xD;
&#xD;
          7. Subject has a history of or an active medical condition(s) that affects absorption or&#xD;
             motility (e.g., Crohn's disease, celiac disease, gastroparesis, short bowel syndrome,&#xD;
             etc.).&#xD;
&#xD;
          8. Subject has tested positive for HIV (due to potential drug-drug interactions between&#xD;
             anti retroviral inhibitors and ABT-263, as well as anticipated ABT-263 mechanism based&#xD;
             lymphopenia that may potentially increase the risk of opportunistic infections and&#xD;
             potential drug-drug interactions with certain anti infective agents).&#xD;
&#xD;
          9. Subject exhibits evidence of other clinically significant uncontrolled condition(s)&#xD;
             including, but not limited to:&#xD;
&#xD;
               -  active systemic fungal infection;&#xD;
&#xD;
               -  diagnosis of fever and neutropenia within one week prior to study drug&#xD;
                  administration.&#xD;
&#xD;
         10. Subject has received any of the following anti-cancer therapies 14 days prior to the&#xD;
             first dose of study drug, or has not recovered to less than grade 2 clinically&#xD;
             significant adverse effect(s)/toxicity(s) of the previous therapies:&#xD;
&#xD;
               -  chemotherapy, immunotherapy, radiotherapy;&#xD;
&#xD;
               -  hormonal therapy (with the exception of hormones for hypothyroidism or estrogen&#xD;
                  replacement therapy [ERT], or agonists required to suppress serum testosterone&#xD;
                  levels [e.g., LHRH, GnRH, etc.] for subjects with prostate cancer if on a stable&#xD;
                  dose for 21 days prior to the first dose of study drug);&#xD;
&#xD;
               -  any investigational therapy, including targeted small molecule agents&#xD;
&#xD;
         11. Subject has received a biologic agent for anti-neoplastic intent within 30 days prior&#xD;
             to the first dose of study drug.&#xD;
&#xD;
         12. Subject is currently receiving or requires anticoagulation therapy or any drugs or&#xD;
             herbal supplements that affect platelet function, with the exception of low-dose&#xD;
             anticoagulation medications, such as heparin, that are used to maintain the patency of&#xD;
             a central intravenous catheter. Note, warfarin is excluded at any dose level.&#xD;
&#xD;
         13. Subject has received aspirin within 7 days prior to the first dose of study drug and&#xD;
             during ABT-263 administration.&#xD;
&#xD;
         14. Subject has consumed grapefruit or grapefruit products within 3 days prior to the&#xD;
             first dose of study drug.&#xD;
&#xD;
         15. In the opinion of the investigator, the subject is an unsuitable candidate to receive&#xD;
             ABT-263.&#xD;
&#xD;
         16. Subject has received a CYP3A inducer within 7 days prior to the first dose of study&#xD;
             drug and during ABT-263 administration.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <results_reference>
    <citation>Xiong H, Pradhan RS, Nada A, Krivoshik AP, Holen KD, Rhodes JW, Gordon GB, Humerickhouse R, Awni WM. Studying navitoclax, a targeted anticancer drug, in healthy volunteers--ethical considerations and risk/benefit assessments and management. Anticancer Res. 2014 Jul;34(7):3739-46.</citation>
    <PMID>24982396</PMID>
  </results_reference>
  <verification_date>January 2011</verification_date>
  <study_first_submitted>September 22, 2009</study_first_submitted>
  <study_first_submitted_qc>September 22, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 23, 2009</study_first_posted>
  <last_update_submitted>November 17, 2017</last_update_submitted>
  <last_update_submitted_qc>November 17, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 21, 2017</last_update_posted>
  <responsible_party>
    <name_title>Mack Mabry, MD, Medical Director</name_title>
    <organization>Abbott</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Navitoclax</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

